Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| PDXHCI002 | A-1210477 | Mcl-1 | Misc | Inf | 0.9814 | -0.0380 | 0.0049 | 0.0000 | Inf | -2.2577 |
| PDX1258 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9970 | -0.0328 | 0.0026 | 0.0000 | Inf | -2.2747 |
| HCC1428 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9911 | -0.0383 | -0.0001 | 0.0000 | Inf | -2.9826 |
| HCC1806 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.8168 | 0.1972 | 0.0004 | 0.0000 | Inf | -2.9998e-08 |
| MDA-MB-134-VI | A-1210477 | Mcl-1 | Misc | Inf | 1.0500 | -0.0366 | -0.0033 | 0.0000 | Inf | -3.0589 |
| SUM149PT | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0138 | -0.0216 | 0.0006 | 0.0000 | Inf | -4.4171 |
| PDXHCI002 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.9869 | -0.0453 | -0.0479 | 0.0000 | Inf | -4.5815 |
| HCC1937 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0406 | -0.0017 | 0.0000 | Inf | -4.6521 |
| CAL-85-1 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0418 | -0.0009 | 0.0000 | Inf | -4.681 |
| PDXHCI002 | Ipatasertib | AKT | PI3K/mTOR | Inf | 1.0500 | -0.0488 | -0.0112 | 0.0000 | Inf | -59.6281 |
| BT-20 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0152 | -0.0415 | -0.0034 | 0.0000 | Inf | -7.4504 |
| MDA-MB-231 | A-1210477 | Mcl-1 | Misc | Inf | 0.9569 | 0.0519 | 0.0034 | 0.0000 | Inf | -8.5977e-09 |
| MDA-MB-436 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0343 | -0.0002 | 0.0000 | Inf | -9.0203 |
| BT-549 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0401 | -0.0011 | 0.0000 | Inf | -9.2879 |
| MDA-MB-134-VI | Saracatinib | SRC | MAPK/nRTK | Inf | 1.0500 | -0.0500 | 0.0181 | 0.0000 | Inf | -Inf |